Factors correlated with hepatitis C and B virus infections among injecting drug users in Tehran, IR Iran

Hepatitis Monthly

Volumn 12, Issue 1, 2012, Pages 23-31

  Amin Esmaeili, Masoumeh ^a   Rahimi Movaghar, Afarin ^a   Razaghi, Emran M ^b   Baghestani, Ahmad Reza ^c   Jafari, Siavash ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Hepatitis viruses; Iran; Prevalence; Risk behavior; Risk factors

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; IRAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; QUESTIONNAIRE; SEX DIFFERENCE; STRUCTURED INTERVIEW; WHO DRUG INJECTION STUDY PHASE II VERSION 2B QUESTIONNAIRE;

EID: 84856703952     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.4332     Document Type: Article

References (54)

1. Razzaghi EM, Rahimi-Movaghar A, Hosseini M, Madani S, Chatterjee A. Rapid Situation Assessment of Drug Abuse in Iran Tehran: Iranian Welfare Organization and UNDCP. 1999; Available From: www.unodc.org/pdf/iran/publications/RSA2000SUMMARY.pdf.
2. Rahimi-Movaghar A, Amin-Esmaeili M, Haghdoost AA, Sadeghirad B, Mohraz M. HIV prevalence amongst injecting drug users in Iran: A systematic review of studies conducted during the decade 1998-2007. Int J Drug Policy. 2011:[Epub ahead of print].
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558-67.
4. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005;8(2):84-90.
5. world health organization. Hepatitis C. 2002; Available From: www.who.int/csr/disease/hepatitis/Hepc.pdf.
6. Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol. 2003;26(2):171-84.
7. Ontario: Public Health Agency of Canada. Epidemiology of Acute Hepatitis C Infection in Canada Results from the Enhanced Hepatitis Strain Surveillance System (EHSSS). Ottawa, Ontario: 2004 [updated 2010 April 29]; Available From: http://www.phac-aspc. gc.ca/sti-its-surv-epi/hcv-epi-eng.php.
8. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36(5 Suppl 1):S93-8.
9. Forouzanfar MH, Mohammad K, Majdzadeh R, Malekzadeh R, Abolhasani F, Mohammadnejad M. [Effectiveness of adolescents' immunization against hepatitis B on burden of the disease in Iran]. Hakim Research J. 2009;9(2):1-11.
10. World Health Organization. Hepatitis B. WHO. 2002 [updated February 2002]; Available From: www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en.
11. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38(10 Suppl 3):S158-68.
12. Karimi A. Seroprevalence of HBV, HCV and HIV among intravenous drug users in Iran. J Clin Virol. 2006;36(Supplement 2):S210-S1.
13. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007;18(5):359-63.
14. Mir-Nasseri MM, Poustchi H, Nasseri-Moghadam S, Nouraie SM, Tahaghoghi S, Afshar P, et al. [HCV in intravenous drug users]. Govaresh. 2005;2(51):80-6.
15. Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009;86(6):902-8.
16. Mohammad Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran. World J Gastroenterol. 2005;11(26):4085-9.
17. Rahbar AR, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy. 2004;15(2):151-5.
18. Zali MR, Aghazadeh R, Nowroozi A, Amir-Rasouly H. Anti-HCV antibody among Iranian IV drug users: is it a serious problem. Arch Iran Med. 2001;4(3):115-9.
19. Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, et al. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis. 2007;13(9):1327-31.
20. Altaf A, Shah SA, Zaidi NA, Memon A, Nadeem ur R, Wray N. High risk behaviors of injection drug users registered with harm reduction programme in Karachi, Pakistan. Harm Reduct J. 2007;4:7.
21. United Nations Programme on HIV/AIDS (UNAIDS), United Nations Development Programme (UNDP). Baseline study of the relationship between IDU, HIV and Hepatitis C among male IDUs in Lahore. 1999 [updated 1999 December]; Available From: http://aidsdatahub.org/en/reference-librarycols2/item/19437.
22. Kuo I, ul-Hasan S, Galai N, Thomas DL, Zafar T, Ahmed MA, et al. High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J. 2006;3:26.
23. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352-8.
24. Sweeting MJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, et al. Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol. 2009;170(3):352-60.
25. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008;122(10):990-1003.
26. Wylie JL, Shah L, Jolly AM. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada. BMC Public Health. 2006;6:229.
27. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J. 2006;3:12.
28. Jafari S, Movaghar A, Craib K, Baharlou S, Mathias R. Socio-cultural Factors Associated with the Initiation of Opium Use in Darab, Iran. Int J Ment Health Addict. (2009); 7(2):376-88.
29. Long J, Allwright S, Barry J, Reynolds SR, Thornton L, Bradley F, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. BMJ. 2001;323(7323):1209-13.
30. Anon C, del Olmo JA, Llovet F, Serra MA, Gilabert S, Rodriguez F, et al. [The hepatitis C virus among the prison population of Valencia]. Rev Esp Enferm Dig. 1995;87(7):505-8.
31. Butler TG, Dolan KA, Ferson MJ, McGuinness LM, Brown PR, Robertson PW. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med J Aust. 1997;166(3):127-30.
32. Zamani S, Farnia M, Tavakoli S, Gholizadeh M, Nazari M, Seddighi AA, et al. A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran. Int J Drug Policy. 2010;21(3):167-72.
33. Oliveira ML, Bastos FI, Telles PR, Yoshida CF, Schatzmayr HG, Paetzold U, et al. Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. Braz J Med Biol Res. 1999;32(9):1107-14.
34. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997;35(12):3274-7.
35. Reyes JC, Colon HM, Robles RR, Rios E, Matos TD, Negron J, et al. Prevalence and correlates of hepatitis C virus infection among street-recruited injection drug users in San Juan, Puerto Rico. J Urban Health. 2006;83(6):1105-13.
36. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol. 2004;33(1):182-8.
37. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645-53.
38. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186(11):1558-64.
39. Raja NS, Janjua KA. Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect. 2008;41(1):4-8.
40. Shapatava E, Nelson KE, Tsertsvadze T, del Rio C. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend. 2006;82(Suppl 1):S35-8.
41. Segurado AC, Braga P, Etzel A, Cardoso MR. Hepatitis C virus coinfection in a cohort of HIV-infected individuals from Santos, Brazil: seroprevalence and associated factors. AIDS Patient Care STDS. 2004;18(3):135-43.
42. Tavakkoli H, Mir-Nasseri MM, Poustchi H, Afshar P, Motalebi MN, Mohammadkhani A, et al. Prevalence and risk factors of hepatitis B infection in injection drug users, Tehran (2001-2002). Hepat Mon. 2008;8(1):29-33.
43. Paez Jimenez A, El-Din NS, El-Hoseiny M, El-Daly M, Abdel-Hamid M, El Aidi S, et al. Community transmission of hepatitis B virus in Egypt: results from a case-control study in Greater Cairo. Int J Epidemiol. 2009;38(3):757-65.
44. Vassilev ZP, Hagan H, Lyubenova A, Tomov N, Vasilev G, Krasteva D, et al. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users. Int J STD AIDS. 2006;17(9):621-6.
45. Backmund M, Meyer K, Schuetz C, Reimer J. Factors associated with exposure to hepatitis B virus in injection drug users. Drug Alcohol Depend. 2006;84(2):154-9.
46. Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H. Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon. 2011;11(1):19-22.
47. Mansson AS, Moestrup T, Nordenfelt E, Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis. 2000;32(3):253-8.
48. Ruan Y, Qin G, Yin L, Chen K, Qian HZ, Hao C, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS. 2007;21(Suppl 8):S39-46.
49. Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J Infect. 2009;58(5):375-82.
50. United Nations Programme on HIV/AIDS (UNAIDS), United Nations Development Programme (UNDP). Joint United Nations Programme on HIV/AIDS. UNAIDS report on the global AIDS epidemic. Geneva. 2010 [updated 2010 November 23]; Available From: www.unaids.org/documents/20101123_PR_GlobalReport_en.pdf.
51. Kral AH, Malekinejad M, Vaudrey J, Martinez AN, Lorvick J, McFarland W, et al. Comparing respondent-driven sampling and targeted sampling methods of recruiting injection drug users in San Francisco. J Urban Health. 2010;87(5):839-50.
52. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis. 2010;14(1):e28-33.
53. Hernandez-Aguado I, Ramos-Rincon JM, Avinio MJ, Gonzalez-Aracil J, Perez-Hoyos S, de la Hera MG. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol. 2001;17(6):539-44.
54. Center for Disease Management; Ministry of Health. Islamic Republic of Iran country report on monitoring of the United Nations General Assembly Special Session (UNGASS) on HIV and AIDS, year 2009. Tehran: 2010 [updated 2010 February]; Available From: http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/2010progressreportssubmittedbycountries/iran_2010_country_progress_report_en.pdf.